TLDR
- Veeva stock jumped ~12% after Q4 earnings beat, with EPS of $2.06 vs. the $1.94 expected.
- Revenue came in at $836 million, up 16% year-over-year, topping the $811 million estimate.
- Q1 guidance of $2.13–$2.14 EPS and $855–$858 million revenue both beat Wall Street forecasts.
- FY2027 revenue is projected at $3.585–$3.6 billion, above the $3.56 billion consensus.
- Ten of the top 20 biopharmaceutical companies have committed to its Vault CRM platform.
Veeva Systems had a rough start to 2026, with the stock down 16% heading into earnings. Wednesday night changed that.
$VEEV (Veeva Systems) #earnings are out: pic.twitter.com/OaJbcGIYeN
— The Earnings Correspondent (@earnings_guy) March 4, 2026
Q4 results came in well above what analysts were expecting. Adjusted EPS landed at $2.06, beating the $1.94 consensus. Revenue grew 16% year-over-year to $836 million, topping the $811 million estimate.
The market responded quickly. VEEV surged around 12% in early Thursday trading.
The beat wasn’t just about the past quarter. Forward guidance gave investors something to hold onto too.
For Q1, Veeva guided EPS of $2.13 to $2.14, ahead of the $2.10 Wall Street was expecting. Revenue guidance of $855 to $858 million also cleared the $853 million estimate.
For the full fiscal year 2027, the company projected revenue of $3.585 to $3.6 billion. That beat the consensus of $3.56 billion. Non-GAAP EPS guidance of $8.85 also topped the $8.60 expected.
The billings guidance drew particular attention from analysts. KeyBanc’s Scott Schoenhaus noted the “healthy billings guidance” helped support valuation during a period of heavy selling pressure on software names.
Schoenhaus, who rates VEEV at Sector Weight, said the results should ease concerns around the broader software sector selloff tied to new AI coding agents.
The CRM Commitment
One detail stood out from the report. Veeva said 10 of the top 20 biopharmaceutical companies have now committed to its Vault CRM platform.
That’s a concrete sign of momentum in one of its most important product lines.
Vault CRM is designed specifically for life sciences companies, handling regulatory and operational workflows that off-the-shelf CRM tools don’t cover well. Winning over big pharma names is a slow process — so these commitments carry weight.
Veeva’s financials back up the growth story. The company carries a net margin of 27.93% and a gross margin of 75.67%. Its current ratio sits at 7.53 and its debt-to-equity ratio is just 0.01.
That’s a clean balance sheet by any measure.
Valuation Check
Before the earnings pop, VEEV’s P/E ratio of 36.67 was sitting near its 10-year low. The P/S ratio of 10.25 and P/B ratio of 4.4 were also near multi-year lows.
Analyst consensus had a target price of $292.17 — well above where the stock was trading.
Institutional ownership stands at 86.51%, which reflects broad confidence from large funds. Insider ownership is lower, at 7.59%, and insiders sold 1,000 shares in the past three months.
The company’s three-year revenue growth rate is 13.4%, and its Altman Z-Score of 19.88 points to strong financial health.
As of early Thursday, VEEV was trading around $201.33, up from roughly $188 before the earnings release.
Considering a new stock? You may want to see what’s on our watchlist first.
Our team at Knockout Stocks follows top-performing analysts and market-moving trends to spot potential winners early. We’ve identified five stocks gaining quiet attention that could be worth watching now. Create your free account to unlock the full report and get ongoing stock insights.Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
